Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 9:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 190 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Myeloid Leukemia
Interventions
Discontinuation of therapy
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Neural Tube Defects, Folic Acid Deficiency, Fortification
Interventions
Salt with folic acid and iodine
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Birmingham, Alabama
Recruiting No phase listed Observational Accepts healthy volunteers

Aging, Geriatric Syndromes and Clonal Hematopoiesis

NCT02604563
Conditions
Geriatrics, Aged, Geriatric Syndromes, Cardiovascular Diseases
Interventions
Cognitive Assessment, Activities of Daily Living Questionnaire, Instrumental Activities of Daily Living, subscale of the OARS, Karnofsky Self-reported Performance Rating Scale, Number of Falls, Physical Health Section, subscale of the OARS, MOS Social Activity Survey, Unintentional Weight Loss, Peripheral Blood Draw, Buccal Swab, Heart Health and Smoking History from BRFSS questionnaire, Gait Speed, Grip Strength, Height and Weight measurements, Blood pressure measurement, Optional bone marrow biopsy, Blood draw for trauma measurements, Femur head donation, Knee bone fragments, Bone marrow aspirate
Other · Genetic · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Sickle Cell Hemoglobinopathies and Bone Health

NCT02306993
Conditions
Sickle Cell Disease, Sickle Cell Trait
Interventions
Healthy volunteers without SCT, Healthy volunteers with SCT, Volunteers with SCD
Other
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
1
States / cities
Farmington, Connecticut
Terminated No phase listed Observational

Adult MDW Dual Cut-Off Accuracy Study

NCT06885528
Conditions
Sepsis
Interventions
Complete Blood Count with differential
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Indianapolis, Indiana • Kansas City, Kansas • Detroit, Michigan + 2 more
Conditions
COVID-19, Long Haul
Interventions
Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach
Drug · Diagnostic Test · Biological + 3 more
Lead sponsor
Well- Konnect Healthcare Services and Research Firm
Network
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Metastatic Breast Cancer
Interventions
Progressive Stretching Group, Nonlinear Aerobic Training, Blood draw, Cardiopulmonary Exercise Testing (CPET)
Behavioral · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Conditions
Diabetes, Chronic Disease, Psychological Distress
Interventions
Immediate Chronic Disease Prevention Program (CDPP), Workplace Equity, Job and Health Supports Employer Intervention, Delayed, attenuated Chronic Disease Prevention Program (CDPP)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

NCT03018223
Conditions
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Hodgkin Lymphoma, Multiple Myeloma
Interventions
Fludarabine, Busulfan, Cyclophosphamide, Total body irradiation (TBI), Peripheral Blood Hematopoietic Cell Transplantation (HCT), Sirolimus (SIR), Mycophenolate mofetil (MMF), Granulocyte-colony stimulating factor (G-CSF)
Drug · Radiation · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Withdrawn Not applicable Interventional Accepts healthy volunteers

Inducing Self-Dehumanization to Examine Oxytocin and Suicide Risk

NCT06710964
Conditions
Mechanistic Self-Dehumanization Condition, Control Condition
Interventions
The Ten Item Personality Inventory, Mechanistic Self-Dehumanization Condition, Debrief, Control Condition, Clinical Interview, Self-Report Measures, Blood Draw
Other · Diagnostic Test
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
alvocidib, daunorubicin hydrochloride, mitoxantrone hydrochloride, cytarabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exogenous Ketones in Healthy Young Adults

NCT03452761
Conditions
Healthy Young Adults
Interventions
Ketone Salts
Dietary Supplement
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Augusta, Georgia
Completed Phase 2Phase 3 Interventional Results available

MEmbranous Nephropathy Trial Of Rituximab

NCT01180036
Conditions
Idiopathic Membranous Nephropathy
Interventions
Rituximab, Cyclosporine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 13 more
Conditions
Fatty Liver
Interventions
possible liver biopsy and serum collection
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Completed Phase 2 Interventional Results available

Targeted Fusion Biopsy of the Prostate

NCT02744534
Conditions
Prostatic Neoplasms
Interventions
FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Lung Cancer
Interventions
Cetuximab, Conformal Thoracic Radiotherapy (CTRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Interventions
6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.
Dietary Supplement
Lead sponsor
CHRISTUS Health
Other
Eligibility
26 Weeks to 32 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Conditions
Rheumatoid Arthritis
Interventions
Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
109
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 83 more
Conditions
End Stage Renal Disease, Anemia
Interventions
Roxadustat, Epoetin Alfa, Placebo
Drug · Other
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more
Conditions
Myelogenous Leukemia, Chronic
Interventions
nilotinib, imatinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
31
States / cities
Los Angeles, California • San Diego, California • Vallejo, California + 27 more
Conditions
High Blood Pressure
Interventions
Control Condition, Regret Lottery
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York